VISGENX
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders. Its programs are based on increasing the expression of a gene known as ELOVL2 which may regulate aging in cells critical for vision.
VISGENX
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2018-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.visgenx.com
Total Employee:
11+
Status:
Active
Total Funding:
8.51 M USD
Similar Organizations
NFlection Therapeutics
NFlection focuses on the development of novel therapies to address the needs of patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Tilden Bio
Tilden Bio develops photosynthetic bioproducts including natural plant essential oils, cannabinoids, and biopharmaceutical proteins.
Valitor
Valitor has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacological properties..
Zavante Therapeutics
Zavante focuses on developing novel therapies to improve the outcomes of hospitalized patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
Tech Coast Angels
Tech Coast Angels investment in Convertible Note - Visgenx
Official Site Inspections
http://www.visgenx.com
- Host name: 159.178.193.35.bc.googleusercontent.com
- IP address: 35.193.178.159
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Visgenx"
Visgenx
Visgenx in Focus. Our goal is to develop therapeutics that slow or halt cellular senescense in macular degeneration and other age-related disorders by “turning back the clock” to a more youthful level of ELOVL2 expression.See details»
Visgenx - Crunchbase Company Profile & Funding
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders. Its programs are based on increasing the expression of a gene known as ELOVL2 which may …See details»
Team - Visgenx
We’re honored to be selected as a 2024 Cool Company. Mission In Focus. Learn more about our goal to develop ELOVL2 based therapeutics to slow or halt aging-related disorders.See details»
Visgenx - LinkedIn
Visgenx | 173 followers on LinkedIn. Therapeutics for Dry Age-Related Macular Degeneration | Visgenx is developing therapeutics based on increasing expression of a gene known as …See details»
Visgenx Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Visgenx. Use the PitchBook Platform to explore the full profile.See details»
Visgenx - Contacts, Employees, Board Members, Advisors & Alumni
Visgenx has 3 board members and advisors, including Frank L. Douglas. Visgenx develops therapeutics to protect against the loss of sight from retinal disorders.See details»
Visgenx - VentureRadar
Visgenx is developing therapeutics to protect against the loss of sight from retinal disorders. Our programs are based on increasing the expression of a gene known as ELOVL2 which may …See details»
Visgenx to present at the American Society of Gene and Cell …
May 15, 2023 · Visgenx, Inc. is a biotechnology company focused on developing gene-based therapeutics for degenerative retinal diseases. Visgenx’ initial product is VGX-0111, a gene …See details»
Visgenx - Funding, Financials, Valuation & Investors - Crunchbase
Visgenx is funded by Tech Coast Angels. Which investors participated in the most funding rounds? Visgenx develops therapeutics to protect against the loss of sight from retinal disorders.See details»
Bringing Visgenx’s Gene Therapy into Focus | Charles …
Dec 7, 2023 · Following the biotechnology company's Type B pre-IND meeting with the FDA, our contract development and manufacturing organization (CDMO) team will begin manufacturing for their lead product, VGX-0111, an AAV …See details»
Visgenx And Charles River Announce Expansion Of Gene Therapy ...
Dec 7, 2023 · Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, announced an extension of their contract development and …See details»
Santosh Vetticaden, MD, PhD, MBA | Heluna Health
Santosh Vetticaden is co-founder of Visgenx, a startup developing treatments for age-related macular degeneration—the leading cause of vision loss worldwide—affecting nearly 80 million …See details»
Science – Visgenx
Our science is based on breakthrough research conducted at the Shiley Eye Institute at the University of California San Diego and exclusively licensed to Visgenx.See details»
Visgenx and Charles River Announce Expansion of Gene Therapy ...
Dec 7, 2023 · Visgenx, Inc. is a biotechnology company focused on developing gene-based therapeutics for degenerative retinal diseases. Visgenx's initial product is VGX-0111, an …See details»
Visgenx and Charles River Announce Expansion of Gene Therapy ...
Dec 7, 2023 · Following Visgenx's Type B pre-IND meeting with the FDA in the summer of 2023, Charles River will begin manufacturing materials for VGX-0111 with the goal of initiating a …See details»
Visgenx and Charles River Announce Expansion of Gene Therapy ...
Dec 7, 2023 · Visgenx, Inc announced an extension of their contract development and manufacturing organization (CDMO) collaboration with Charles River Laboratories …See details»
Visgenx to present at the American Society of Gene and Cell …
May 15, 2023 · Visgenx, Inc. is a biotechnology company focused on developing gene-based therapeutics for degenerative retinal diseases. Visgenx' initial product is VGX-0111, a gene …See details»
Visgenx and Charles River Announce Expansion of Gene Therapy ...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.See details»
Therapeutic Strategy – Visgenx
Learn more about our goal to develop ELOVL2 based therapeutics to slow or halt aging-related disorders.See details»
Visgenx Announces Positive Results from a Key Translational Study …
SAN DIEGO, June 27, 2023 /PRNewswire/ -- Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced positive data …See details»